Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop could ease pain of Sight-Saving injections

NCT ID NCT05747430

Symptom relief Sponsor: iRenix Medical, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new antiseptic called IRX-101 against the standard povidone-iodine in 155 people receiving eye injections for retinal disease. The goal was to see if IRX-101 reduces pain and corneal damage after the injection. Researchers measured safety and corneal staining to compare the two treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IRX-101 (a novel antiseptic solution)
What this could lead to
If it works, this could make eye injections for retinal disease less painful and reduce damage to the cornea, improving patient comfort.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 155 participants. The results may not apply to everyone, and the new antiseptic might not be better than the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

155 people

The number who actually took part.

Started

Feb 2023

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Capable of giving informed consent 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, ≥ 18 years of age and receiving intravitreal anti-VEGF injections in one or both eyes Exclusion Criteria: 1. Current or past diagnosis of endophthalmitis 2. Current diagnosis of uveitis 3. Monocular patients (vision 20/100 or worse in one eye) who are receiving injections in the better seeing eye 4. Current use of viscous lidocaine products for ocular anesthesia prior to IVT 5. Currently receiving intravitreal steroid injections 6. Concurrent participation in another clinical trial 7. Females who are pregnant, planning to become pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinal disease

Contacts and locations

Locations

  • Charleston Neuroscience Institute

    Ladson, South Carolina, 29456, United States

  • Coastal Eye Surgeons, LLC

    Greenwich, Connecticut, 06830, United States

  • Edward Wood, MD

    Round Rock, Texas, 78681, United States

  • Erie Retina Research, LLC

    Erie, Pennsylvania, 16507, United States

  • Mississippi Retina Associates

    Madison, Mississippi, 39110, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Consultants of Texas

    Katy, Texas, 77494, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.